Sun Life Malaysia Allocates over RM1 Million For Covid-19 Side-Effect And Complication Funds

Sun Life Malaysia Assurance Berhad and Sun Life Malaysia Takaful Berhad has established a support measure for its clients who are affected by the outbreak under two funds, the Covid-19 Vaccine Complication Fund and the RM1 million Covid-19 Medical Assistance Fund.

These two funds mainly ensure assistance for post-vaccination side-effects and coverage against rising hospital treatment costs due to Covid-19 infection by referral by the Ministry of Health (MoH) Malaysia.

Raymond Lew, Chief Executive Officer (CEO) and Country Head of Sun Life Malaysia said, “After a full year of battling the pandemic together, the vaccine programme has finally brought us to the next stage of recovery and Sun Life Malaysia strives to continue supporting our clients throughout this process in line with our purpose of empowering them to achieve lifetime financial security and live healthier lives.”

The fund provide medical assistance benefit of up to RM5,000 for treatments requiring hospitalisation and a special death benefit of RM7,500 following death due to serious Adverse Event Following Immunisation (AEFI).

Meanwhile, the RM1 Million Covid-19 Medical Assistance Fund will financially assist those affected by Covid-19 with reimbursements of hospital treatment costs endorsed by the MoH.

“While there are natural concerns over the vaccination’s efficacy, we are doing our part to ease these doubts by establishing the Vaccine Complications Fund to ensure clients are more confident in taking the vaccine, knowing they are protected should any complications arise,” Raymond said.

“We will do everything we can to safeguard Malaysians through these tough times and helping them towards a brighter future ahead,” Raymond added. 

Previous articlePersolkelly Announces A New Brand Identity To Meet Workforce Needs
Next articleSolution Group Berhad Signs Supply Agreement Of 3.5 Million Doses Of Convidicea Vaccine with MoH

LEAVE A REPLY

Please enter your comment!
Please enter your name here